Zobrazeno 1 - 10 of 149 pro vyhledávání: '"S. W. SCHALM"'
1
High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitisNote
Autor: H R, van Buuren, van Hoogstraten HJE, T, Terkivatan, S W, Schalm, F P, Vleggaar
Publikováno v: Journal of Hepatology. 33:543-548
Traditionally, autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) are regarded as separate disease entities. We report on a group of patients that suggests the existence of an overlap syndrome of the two conditions and on the prevale
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e63bc6c278d32c98efa74024cb318866
https://doi.org/10.1034/j.1600-0641.2000.033004543.x
Zobrazit plný text záznamu
2
Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa
Autor: Roberto Corrocher, G. Giustina, S W Schalm, G Realdi, Giovanna Fattovich
Publikováno v: Hepatology, 26, 1338-1342. John Wiley & Sons Ltd.
The aim of this study was to evaluate whether interferon alfa (IFN-alpha) treatment-associated virological and biochemical remission improves survival in a cohort of 90 white patients with compensated cirrhosis caused by hepatitis B (Child A) followe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8a0fee87e287a10a1b7ec1027d390b8
https://doi.org/10.1002/hep.510260536
Zobrazit plný text záznamu
3
Clinical use of interferon in hepatitis B and C
Autor: S W, Schalm
Publikováno v: Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie. 71(1-2)
The concept of antiviral therapy with interferon for chronic hepatitis B emerged in the middle of the seventies and was supported by the suppressive effect of human interferon on HBV-DNA polymerase levels in 3 patients. This effect of leukocyte inter
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::eef616c37264ba30f45428489d8cef39
https://pubmed.ncbi.nlm.nih.gov/19739400
Zobrazit plný text záznamu
4
Treatment of chronic hepatitis B virus infection - Dutch national guidelines
Autor: E H C J, Buster, K J, van Erpecum, S W, Schalm, H L, Zaaijer, J T, Brouwer, H C, Gelderblom, R J, de Knegt, C, Minke Bakker, H W, Reesink, H L A, Janssen
Publikováno v: The Netherlands journal of medicine. 66(7)
The development of this guideline was initiated and coordinated by the Netherlands Association of Gastroenterologists and Hepatologists (Nederlandse Vereniging van Maag-Darm-Leverartsen). The aim is the establishment of national standards in the eval
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e9b43b3df7d33281771e47dabfb6ce71
https://pubmed.ncbi.nlm.nih.gov/18663260
Zobrazit plný text záznamu
5
Treatment of chronic hepatitis C virus infection - Dutch national guidelines
Autor: J, de Bruijne, E H C J, Buster, H C, Gelderblom, J T, Brouwer, R J, de Knegt, K J, van Erpecum, S W, Schalm, C M, Bakker, H L, Zaaijer, H L A, Janssen, H W, Reesink
Publikováno v: The Netherlands journal of medicine. 66(7)
The development of this guideline was initiated and coordinated by the Netherlands Association of Gastroenterologists and Hepatologists (Nederlandse Vereniging van Maag-Darm-Leverartsen). The aim is the establishment of practical guidelines in the ev
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a065b20332e2090efb55209e357a50af
https://pubmed.ncbi.nlm.nih.gov/18663263
Zobrazit plný text záznamu
7
[Changes in the management of patients with side effects from the treatment of hepatitis C]
Autor: G, Bezemer, S W, Schalm, A R, van Gool, R J, de Knegt
Publikováno v: Nederlands tijdschrift voor geneeskunde. 151(9)
Since hepatitis C can be treated more and more successfully, treatment should be considered in every patient. In some of the patients infected by viral genotype I, the duration of treatment can be shortened: 24 weeks instead of 48 weeks. Maintaining
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f00c94c619dc80c1b52ddf063e1bf32c
https://pubmed.ncbi.nlm.nih.gov/17373393
Zobrazit plný text záznamu
9
The treatment of hepatitis C: history, presence and future
Autor: J M, Vrolijk, R J, de Knegt, B J, Veldt, H, Orlent, S W, Schalm
Publikováno v: The Netherlands journal of medicine. 62(3)
The treatment of chronic hepatitis C has made remarkable progress over the past two decades. For interferon-alpha monotherapy, sustained virological response rates were between 2 and 9% in genotype 1 and between 16 and 23% in genotypes 2 and 3. By ad
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f72c4f841dbffdfcfa6f9a163a41ffc9
https://pubmed.ncbi.nlm.nih.gov/15209471
Zobrazit plný text záznamu
10
Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen
Autor: J W Wladimiroff, S W Schalm, J A Mazel, R A Heijtink, A S M Nuijten, P. M. Grosheide, G. C. M. L. Christiaens
Publikováno v: BMJ. 311:1197-1199
Objective: To develop a low cost, high compliance screening programme for identification of carriers of hepatitis B surface antigen in the obstetric population of the Netherlands. Design: A seven year open, descriptive study of screening for hepatiti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5151e0078b94502f04c60c57db2e128e
https://doi.org/10.1136/bmj.311.7014.1197
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje